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Abstract
Introduction Cartilage oligomeric matrix protein (COMP) is a
homopentameric protein in cartilage. The development of
arthritis, like collagen-induced arthritis (CIA), involves cartilage
as a target tissue. We have investigated the development of CIA
in COMP-deficient mice.
Methods COMP-deficient mice in the 129/Sv background were
backcrossed for 10 generations against B10.Q mice, which are
susceptible to chronic CIA. COMP-deficient and wild-type mice
were tested for onset, incidence, and severity of arthritis in both
the collagen and collagen antibody-induced arthritis models.
Serum anti-collagen II and anti-COMP antibodies as well as
serum COMP levels in arthritic and wild-type mice were
measured by enzyme-linked immunosorbent assay.
Results COMP-deficient mice showed a significant early onset
and increase in the severity of CIA in the chronic phase, whereas
collagen II-antibody titers were similar in COMP-deficient and
wild-type controls. COMP antibodies were not found in wild-
type mice. Finally, COMP-deficient and wild-type mice
responded similarly to collagen antibody-induced arthritis,
indicating no difference in how collagen II antibodies interact
with COMP-deficient cartilage during the initial stages of
arthritis.
Conclusions COMP deficiency enhances the early onset and
development of chronic arthritis but does not affect collagen II
autoimmunity. These findings accentuate the importance of
COMP in cartilage stability.
Introduction
Rheumatoid arthritis (RA) is a human autoimmune disease that
affects the synovial membranes of the peripheral joints. RA
characteristically involves the infiltration of leukocytes into the
synovium, which undergo inflammation and swelling [1]. RA in
humans is a heterogenous disease, and the environmental and
genetic factors involved in its manifestation and perpetuation
may vary from individual to individual. Although there is an HLA
association, the classification of RA is based primarily on diag-
nostic criteria [2], of which the presence of joint swelling in the
hands, the duration and symmetry of the joint swelling, and
abnormal levels of rheumatoid factors are some examples.
More recently, it has been shown that the serum levels of car-
tilage oligomeric matrix protein (COMP) are elevated in a high
proportion of patients suffering from RA [3-5], which not only
is of diagnostic interest but also may indicate that this cartilage
protein is involved in the disease process.
In 1977, Trentham and colleagues [6] developed the collagen-
induced arthritis (CIA) model in rats as a model for the study
of RA. Since then, several modified CIA models have been
developed in mice, and CIA is still one of the most common
animal models of RA. The CIA model shares some important
features with RA, namely major histocompatibility complex
(MHC) association and the fact that peripheral joints primarily
are affected and that the disease can be divided into an acute
CAIA: collagen II antibody-induced arthritis; CIA: collagen-induced arthritis; CII: collagen II; COMP: cartilage oligomeric matrix protein; ELISA: 
enzyme-linked immunosorbent assay; LPS: lipopolysaccharide; MED: multiple epiphyseal dysplasia; MHC: major histocompatibility complex; PBS: 
phosphate-buffered saline; PCR: polymerase chain reaction; PSACH: pseudoachondroplasia; RA: rheumatoid arthritis; TSP: thrombospondin.Arthritis Research & Therapy    Vol 10 No 6    Geng et al.
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and a chronic stage. In the CIA model, an immunization against
one specific cartilage protein, collagen II (CII), starts an
autoimmune reaction leading to arthritis. In the chronic stage
of the disease, when the erosion of the cartilage is taking
place, it is possible that immune reactions to other cartilage
proteins are initiated and contribute to the disease course. In
fact, the immunization with other cartilage proteins in some
cases will cause a disease similar in type to CIA, which has
been shown to be immunized with COMP [7].
COMP is a 524-kDa homopentameric extracellular matrix glyc-
oprotein and a member of the thrombospondin (TSP) family
[8]. To date, five members of the TSP family have been identi-
fied. Among them, TSP-1 and TSP-2 contain three identical
subunits [9-12], whereas TSP-3, TSP-4, and COMP (also
called TSP-5) contain five identical subunits [8,13,14]. COMP
is present in cartilage, tendon, vitreous of the eye, and vascular
and smooth muscle cells [15,16]. In adult articular cartilage,
COMP is most abundant in the inter-territorial matrix [17]. As
previously mentioned, COMP has recently been found to be a
useful biomarker for pathological conditions since the detec-
tion of COMP fragment levels in synovial fluid or serum can be
used to assess the presence and progression of arthritis [3-5].
The importance of COMP for cartilage structure and function
is underscored further by the findings that COMP mutations
cause human skeletal dysplasia, pseudoachondroplasia
(PSACH), and multiple epiphyseal dysplasia (MED) [18,19].
The clinical features of PSACH and MED are mild to severe
short limbs, joint laxity, and early osteoarthritis. Although the
clinical features are similar, PSACH is normally more severe
than MED [20-22].
We have previously generated COMP-deficient mice to study
the role of COMP in cartilage tissues [23]. Surprisingly, the
total absence of COMP did not result in an obvious pheno-
type, and the COMP-deficient mice did not show any abnor-
malities in their cartilage and skeletal tissues [23]. The function
of COMP in cartilage remains unknown. Interestingly, mice
deficient in the cartilage matrix protein collagen type IX, which
(like COMP-deficient mice) appear phenotypically normal,
showed cartilage properties significantly different from those
of the wild-type mice when investigated in the CIA and CII anti-
body-induced arthritis (CAIA) models. Apparently, the micro-
structure of the cartilage of collagen IX-deficient mice had
changed in a way that anti-CII antibodies could more easily
reach immunogenic CII epitopes, which in turn caused a more
severe arthritis in the acute stage of the disease [24]. Thus, the
absence of one cartilage protein can affect how effector mol-
ecules of the immune system reach and bind other cartilage
proteins.
To test whether COMP deficiency, like collagen IX deficiency,
influences the antigenic/immunogenic properties of the carti-
lage, we decided to study COMP-deficient mice in the CIA
and CAIA models. In this paper, we present results indicating
that COMP deficiency makes arthritic mice develop an early
onset and more severe disease during the chronic phase. We
also present data showing that the exacerbation of the disease
in arthritic COMP-deficient mice is independent of how path-
ogenic antibodies penetrate the cartilage in the acute stage of
the disease, which is contrary to the case in collagen IX-defi-
cient mice [24]. Finally, a role for COMP in the cartilage repair
mechanism is discussed as a possible explanation for the




The generation of COMP-deficient 129/Sv mice has been
described previously [23]. COMP-deficient 129/Sv mice were
backcrossed for 10 generations to B10.Q mice (originally
obtained from The Jackson Laboratory, Bar Harbor, ME, USA),
which are susceptible to CIA. The mice were kept in a climate-
controlled environment with 12-hour light-dark cycles, housed
in polystyrene cages containing wood shavings, and provided
with standard rodent chow and water ad libitum in the animal
house of the Department of Pathology, Lund University (Lund,
Sweden). All experiments described here were performed on
age-matched mice between 8 and 10 weeks of age. The Lund-
Malmö laboratory animal ethics committee approved the ani-
mal experiments described in this article.
Induction and evaluation of collagen II-induced arthritis
The mice were injected subcutaneously at the base of the tail
with 100 μg of rat CII emulsified in 0.1 M acetic acid combined
with an equal amount of complete Freund's adjuvant (Difco
Laboratories, now part of Becton Dickinson and Company,
Franklin Lakes, NJ, USA). CII was purified from the Swarm rat
chondrosarcoma as previously described [25]. At day 30 after
primary CII immunization, a booster injection of 50 μg of rat CII
in incomplete Freund's adjuvant was given at the same loca-
tion. Arthritis development was monitored in all four limbs by
means of a macroscopic scoring system [26]. Briefly, one
point was given for each swollen or red toe, one point for each
swollen joint (metatarsal phalangeal joints, metacarpal phalan-
geal joints, proximal interphalangeal joints, and distal inter-
phalangeal joints), and five points for a swollen ankle
(maximum score per limb was 15 and maximum score per
mouse was 60). The mice typically were examined three times
per week up to 5 months after immunization.
Induction and evaluation of collagen II antibody-induced 
arthritis
To induce CAIA, the mice were injected with a mixture of equal
concentrations of sterile filtered CIIC1 (IgG2a), M2139
(IgG2b), CIIC2 (IgG2b), and UL1 (IgG2b) monoclonal anti-
bodies against different CII epitopes (C1, J1, D3, and U1)
[27]. Mice were injected intravenously with 0.33 mL of anti-
body mixture as a single dose on day 0. Subsequently, on day
8, lipopolysaccharide (LPS) from Escherichia coli 055:B5 (25Available online http://arthritis-research.com/content/10/6/R134
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μg/mouse) was injected intraperitoneally to enhance the inci-
dence and severity of arthritis. The mice were monitored daily
for arthritis development after antibody injection (both before
and after LPS injection), using the same macroscopic scoring
system as described above for CIA.
Production of recombinant mouse cartilage oligomeric matrix
proteinA mouse COMP cDNA clone was kindly provided by
Liu Chan Ju (Department of Orthopaedic Surgery, New York
University Hospital for Joint Diseases, New York, NY, USA). A
cDNA fragment corresponding to nucleotides 72 to 2,282 in
the mouse COMP reference sequence [GenBank
NM016685] and comprising the entire COMP open reading
frame, except the signal peptide, was amplified by polymerase
chain reaction (PCR), using primers mCOMP-TNT-F (5'-CAG-
GGCCAGATCCCGCTG-3') and mCOMP-TCG-R (5'-CGT-
GCTAGCCTAAACTCTCTGCAGCC-3'), introducing a
downstream Nhe I restriction site. The PCR product was sub-
cloned into plasmid pCR-SCRIPT and sequenced. This
revealed a mutation (C493T, Thr160Ile) compared with the
reference sequence. This may represent a naturally occurring
allele, but since the mutated residue is conserved in human,
chimp, bovine, equine, and rat COMP, the cDNA sequence
was corrected by site-directed mutagenesis using the Quik-
Change kit (Stratagene, La Jolla, CA, USA) and primers Fwd-
MUT (5'-CCCCCTGGGTTCAGCGGGCCCACCCACGA
GGGCGTGGGACTGACC-3') and RevMUT (5'-
GGTCAGTCCCACGCCCTCGTGGGTGGGCCCGCT-
GAACCCAGGGGG-3'). The corrected COMP cDNA frag-
ment was isolated by digestion with Bgl I and Not I restriction
enzymes and ligated into the corresponding sites in the
expression vector pCEP4-BM40-hisEK. The resulting mouse
COMP expression plasmid was transfected into 293-c18 cells
(ATCC CRL-10852) and selected with hygromycin. After-
wards, conditioned medium was collected and the his-tagged
recombinant mouse COMP was purified through Ni2+-metal
chelating and MonoQ ion exchange chromatography. Protein
content was determined by measuring absorbance at 280 nm,
using a calculated extinction coefficient of 71,390/M per cm.
Determination of serum levels of antibodies against 
cartilage oligomeric matrix protein and collagen II
Antibody levels against COMP in serum were analyzed by
enzyme-linked immunosorbent assay (ELISA) using recom-
binant mouse COMP. Recombinant COMP (50 μL/well; 5 μg/
mL in phosphate-buffered saline (PBS), pH 7.4) was used for
coating overnight at 4°C, and plates were pre-blocked with
1% bovine serum albumin in PBS to avoid background distur-
bance. All washings were performed by using PBS with 0.1%
Tween 20 (pH 7.4). The serum was diluted in PBS and ana-
lyzed in duplicate, and then biotin-conjugated goat anti-mouse
heavy- and light-chain antibodies were added, followed by
europium-labeled streptavidin (Delfia, Wallac OY, Turku, Fin-
land), and enhancement solution (Delfia Wallac); the amount
of antibody was detected by dissociation-enhanced time-
resolved fluoroimmunoassays research fluorometer. Serum
samples from COMP-induced arthritis mice were used as a
positive control. Antibody titers against CII in serum were
determined by sandwich ELISA similar to COMP antibody
assay, except the plates were coated with 10 μg/mL CII [28].
Antibody levels are shown as fluorescence units.
Determination of serum levels of cartilage oligomeric 
matrix protein
Serum concentration of COMP was determined by a compet-
itive ELISA [3]. Rat COMP was used for coating the microtiter
plates and for preparing the standard curve included in each
plate. Plates were blocked with 1% BSA in PBS for 2 hours at
room temperature. After blocking, serum samples were co-
incubated with rabbit polyclonal antiserum against rat COMP
(generously provided by Dick Heinegård, Section for Connec-
tive Tissue Biology, Lund University) and incubated for 2 hours
at room temperature. The amount of COMP was estimated
after incubation with an alkaline phosphatase-conjugated
swine anti-rabbit isotype-specific antibody (DakoCytomation,
Glostrup, Denmark) and phosphatase substrate (Sigma-
Aldrich, St. Louis, MO, USA) as substrate followed by detec-
tion at 405 nm in a Spectra Max plate reader (Molecular
Devices Corporation, Sunnyvale, CA, USA).
Statistics
Quantitative data are expressed as mean ± standard error of
the mean, and significance analysis of disease onset was per-
formed by using the Student t test. Severity comparison was
performed by the Mann-Whitney U test. All results obtained
from COMP-deficient mice were compared with those
obtained from B10.Q wild-type littermate controls. Differences
were considered to be statistically significant for P values of
less than 0.05.
Results
Generation of B10.Q cartilage oligomeric matrix protein-
deficient mice
To determine a possible effect of COMP deficiency on CIA
and CAIA, we backcrossed COMP-deficient 129/Sv mice
with B10.Q mice. The B10.Q mouse has a C57BL/10 genetic
background and a DBA/1-derived congenic fragment contain-
ing the MHC class II gene Aq molecule allowing an immune
response to CII [29]. The experiments were performed in ani-
mals after backcrossing for 10 generations to B10.Q mice.
Remaining differences in the genome background were
excluded by littermate-controlled experiments. COMP-defi-
cient mice in B10.Q background have no microscopic or mac-
roscopic sign of osteoarthritis or other pathologies in a large
number of normal young and old (more than 1 year) mice (data
not shown).Arthritis Research & Therapy    Vol 10 No 6    Geng et al.
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Early onset and increased severity in chronic phase of 
collagen II-induced arthritis in cartilage oligomeric 
matrix protein-deficient mice
To test whether COMP deficiency makes the cartilage more
susceptible to CIA, we immunized the mice with heterologous
rat CII. The male mice in the COMP-deficient and wild-type
groups started to develop arthritis on day 32, and the disease
course could be divided into two phases, acute phase (from
days 32 to 66) and chronic phase (from days 66 to 158),
because there was a decrease in the mean arthritis score after
day 66 in wild-type mice. COMP deficiency led to early onset
of the disease, with a mean onset of arthritis at 37.5 ± 2.81
days in COMP-deficient mice compared with 48.4 ± 13.7
days in the wild-type littermate group (P < 0.05). There was no
change in severity during the acute phase between COMP-
deficient mice and wild-type mice (Figure 1). In the chronic
phase of the disease course, the mean arthritis score in
COMP-deficient mice continued to increase. COMP-deficient
mice developed significantly more severe arthritis during the
chronic phase of the disease course compared with wild-type
mice (Figure 1). The incidence of arthritis in COMP-deficient
male mice (75%) was not significantly different compared with
wild-type mice (88.8%). For the female mice, both COMP-
deficient and wild-type mice were less susceptible to CIA: only
two of eight COMP-deficient female mice developed arthritis,
and two of nine wild-type mice developed arthritis. Because of
this low incidence of arthritis, it was not possible to compare
the onset day and the severity of arthritis developed among the
female mice.
Cartilage oligomeric matrix protein deficiency did not 
alter collagen II-specific antibody synthesis
Antibodies have been shown to play an important role in arthri-
tis onset and the severity of the disease [30,31]. Both COMP-
deficient mice and wild-type mice mounted high-antibody tit-
ers to CII. Antibody levels, however, were found to be similar
in the COMP-deficient and wild-type mice at days 30, 130,
and 160 (Figure 2), demonstrating that COMP deficiency in
cartilage had no significant effect on CII-specific antibody
response.
Antibodies to cartilage oligomeric matrix protein did not 
play a role in disease induction
The serum COMP level is used as a biomarker both in humans
and in experimental animals to detect ongoing inflammation in
the joints as well as a measure of severity of the arthritis
induced [3-5]. Hence, we measured the COMP levels in
arthritic animals and found released COMP fragments in the
serum collected from arthritic wild-type mice (Figure 3a). How-
ever, we could not detect antibodies to COMP in the serum at
any point during the arthritic disease course from days 30 to
160, suggesting that antibodies to COMP are not involved in
the pathological process of CIA (Figure 3b).
Cartilage oligomeric matrix protein-deficient mice and 
wild-type mice showed similar responses to collagen II 
antibody-induced arthritis
Figure 1
Cartilage oligomeric matrix protein (COMP)-deficient B10.Q mice show earlier onset and more severe collagen II (CII)-induced arthritis Cartilage oligomeric matrix protein (COMP)-deficient B10.Q mice show earlier onset and more severe collagen II (CII)-induced arthritis. Arthritis was 
induced on day 0 by a subcutaneous injection of rat CII emulsified in complete Freund's adjuvant in COMP-deficient mice and B10.Q mice. The 
mice were boosted on day 30 with an injection of rat CII in incomplete Freund's adjuvant. Arthritis severity was followed for 158 days. Arthritis inci-
dence (a) and mean arthritis score (b) are indicated. The data are representative of three experiments. Asterisks indicate significant differences 
between COMP-deficient mice (n = 8) and wild-type mice (n = 9) (P < 0.05).Available online http://arthritis-research.com/content/10/6/R134
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To induce CAIA, the mice were injected with a standard cock-
tail of CIIC1, M2139, CIIC2, and UL1 monoclonal antibodies
directed against dominant B-cell epitopes of CII. We observed
a possible influence on disease onset in COMP-deficient
mice, with the mean onset day in COMP-deficient mice of 5.1
± 3.35 days compared with 6.85 ± 3.4 days in control mice.
This difference was not significant. Consistent with CIA
results, no difference was found in the incidence of arthritis
between COMP-deficient and wild-type littermate controls
(Figure 4a). Both groups developed arthritis with a peak
around day 12, which subsided with the same rate. There was
no difference in mean arthritis score between these two
groups during the rapid phase of disease progress (Figure
4b).
Discussion
COMP is a major non-collagenous component of cartilage and
contributes about 1% of the wet weight of articular cartilage
[15]. COMP has been studied intensively due to the fact that
COMP mutations are associated with musculoskeletal dis-
ease [18,19]. However, the biological function of COMP in
cartilage remains unknown. We have previously generated
COMP-null mice and shown that they have normal skeletal
development. This raises the argument that COMP in cartilage
may be functionally redundant
Here, we show that COMP-deficient mice develop an early-
onset CIA and more severe arthritis during the chronic phase
of the disease.
The findings that COMP-deficient mice develop severe
autoimmune CIA indicate that COMP deficiency makes the
cartilage more susceptible to an inflammatory attack. Antibod-
ies play a critical role in the initiation of CIA [30,31]. The
COMP-deficient mice developed the same high levels of anti-
CII antibodies as wild-type mice during CIA. We have previ-
ously reported that collagen IX-deficient mice are more sus-
ceptible to CAIA, most likely due to the higher penetrance of
anti-CII antibodies into cartilage [24]. Accordingly, there might
be a difference in accessibility of antibodies to cartilage matrix
due to COMP deficiency. However, the susceptibility to CAIA
was not enhanced in COMP-deficient mice although there is a
possible trend toward an earlier onset. COMP, however, is
released systemically during CIA and it is likely that these frag-
ments affect T cell-dependent immune regulation, a phenome-
non that may be different in COMP-deficient mice. The nature
of the T-cell response in wild-type versus COMP-deficient ani-
mals requires another set of experiments as the circulating
COMP affects T-cell tolerance, and we therefore need to
determine the major T-cell epitopes. Again, since there were
no changes in anti-CII antibody titers and anti-CII antibodies
are T cell-dependent, the T-cell responsiveness as such is not
an obvious explanation.
It has been reported that pentameric COMP binds to collagen
I/collagen II [32] and collagen IX [33] with high affinity via the
C-terminal globular domains (Figure 5). Indeed, COMP
appears to function as an accelerator of collagen fibril forma-
tion [34]. These COMP-collagen interactions may be crucial
for the formation of a cartilage collagen network. It is possible
Figure 2
Collagen II (CII) antibody levels in cartilage oligomeric matrix protein  (COMP)-deficient and wild-type mice Collagen II (CII) antibody levels in cartilage oligomeric matrix protein 
(COMP)-deficient and wild-type mice. Serum was taken at days 0, 30, 
130, and 160 after CII immunization and analyzed for CII antibody lev-
els. No CII antibodies were detected in wild-type or COMP-deficient 
mice at day 0. Data are representative of three experiments on COMP-
deficient mice (n = 8) and wild-type mice (n = 9). Filled bars (COMP-
deficient) and open bars (wild-type) show mean values and standard 
error (error bars).
Figure 3
Serum cartilage oligomeric matrix protein (COMP) and COMP antibody  levels in mice with collagen II-induced arthritis (CIA) (n = 8) Serum cartilage oligomeric matrix protein (COMP) and COMP antibody 
levels in mice with collagen II-induced arthritis (CIA) (n = 8). Serum 
from wild-type B10.Q mice with CIA was taken at days 0, 30, 130, and 
160 after collagen II immunization. COMP (a) and COMP antibodies 
(b) in serum were analyzed. The negative (-) control was serum from 
COMP-deficient mice (n = 7), and the positive (+) control was serum 
from COMP-deficient mice injected with COMP (n = 7).Arthritis Research & Therapy    Vol 10 No 6    Geng et al.
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that COMP deficiency leads to instability and changed expo-
sure of concealed epitopes, and it would be interesting to
study whether new epitopes on CII and CIX indeed are
exposed and, if so, whether this could mediate pathologic
changes in COMP-deficient mice. Furthermore, COMP may
have direct effects on chondrocytes (for example, through
interaction with integrins [21]), which may regulate chondro-
cyte cellular activities and phenotypic development. These
functions of COMP might be especially important during
remodeling of cartilage after injury or during inflammatory con-
ditions. In the present study, the observation that COMP-defi-
cient mice show a more severe arthritis during the chronic
phase of CIA, but not during the acute phase, supports the
hypothesis that COMP is important in cartilage repair proc-
esses and thus in cartilage regeneration and remodeling.
The primary target cartilage antigen in CIA is CII, which initi-
ates the autoimmune reaction leading to arthritis. In the course
of the disease, when the erosion of the cartilage is taking
place, it is possible that immune reactions to other cartilage
proteins are initiated and contribute to the disease course. In
Figure 4
Collagen antibody-induced arthritis (CAIA) in cartilage oligomeric matrix protein (COMP)-deficient and wild-type B10.Q mice Collagen antibody-induced arthritis (CAIA) in cartilage oligomeric matrix protein (COMP)-deficient and wild-type B10.Q mice. CAIA was induced by 
intravenous transfer of cocktail of four monoclonal antibodies reacting with collagen II epitopes (CIIC1, M2139, CIIC2, and UL1) on day 0, and 
lipopolysaccharide (LPS) (25 μg per mouse) was injected intraperitoneally on day 8. Mice were monitored for arthritis development on the indicated 
days. Arthritis incidence (a) and mean arthritis score (b) are indicated. Data were obtained from two identically performed experiments: COMP-defi-
cient mice (n = 13) and wild-type mice (n = 15).
Figure 5
Schematic picture of interactions of cartilage oligomeric matrix protein (COMP) with collagen II and collagen IX Schematic picture of interactions of cartilage oligomeric matrix protein (COMP) with collagen II and collagen IX. In cartilage, collagen II is the main 
collagen and makes up a fiber network that provides a cohesive framework. COMP binds via each C-terminal globule to triple-helical collagen II with 
high affinity. The binding between COMP and triple-helical collagen domains influences collagen fibril assembly. In addition, interactions between 
COMP and collagen IX provide the potential for crossbridging collagen fibrils to form a cartilage collagen network. Figure is modified from 
Heinegård and colleagues [35].Available online http://arthritis-research.com/content/10/6/R134
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the CIA model, COMP was found to be released to serum.
Using COMP-deficient mice as a negative control and mice
immunized with COMP to induce arthritis as a positive control,
we investigated whether there was an immune response
against COMP during CIA. We did not find COMP antibodies
at any point during the whole disease course, suggesting no
involvement of immune response against COMP in CII-
induced arthritis.
Conclusion
COMP deficiency in mice subjected to CIA did not affect
either incidence or anti-CII antibody titers but caused a signif-
icant early onset and increase in the severity of the disease
during the chronic phase of arthritis. Arthritic B10.Q mice suf-
fering from CIA did not respond immunologically to COMP by
means of COMP antibody synthesis. Results of the CAIA
study demonstrate that antibodies accessed CII epitopes sim-
ilar in COMP-deficient and COMP-sufficient mice. Our results
emphasize the importance of COMP in cartilage stability, and
the mechanism underlying the exacerbation of CIA in COMP-
deficient mice is assumed to be found in COMP-dependent
changes in the cartilage erosion/repair process.
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